Biomea Fusion (BMEA)

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

De Biomea Fusion, Inc. Common Stock (BMEA) aandelenkoers vandaag is $ 1,42, wat een +3,65% beweging weergeeft sinds de markt geopend. De marktkapitalisatie van het bedrijf staat op $ 100,40 mln., met een dagelijks tradevolume van $ 1,03K aandelen. De vorige slotkoers was $ 1,37.

Klaar om aan de slag te gaan? Volg de onderstaande stappen, of lees onze gids over hoe je Biomea Fusion aandelen op Kraken kunt kopen vanaf € 10.